This article is more than 5 years old. Information may no longer be current.

Eli Lilly’s Humulin KwikPen now available in US

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Eli Lilly’s Humulin R U-500 KwikPen 500 units/mL is now available at pharmacies in the United States, according to a company press release.

The KwikPen was approved by the FDA in January and can be used to treat high blood glucose in people with type 1 and type 2 diabetes who need more than 200 unites of insulin per day. This is the first FDA-approved insulin that is five times more concentrated than U 100 and allows users to inject up to 80% less liquid while still getting the needed dose, according to the company.

“People with diabetes and severe insulin resistance who have become poorly responsive to the effects of insulin may require much higher insulin doses — more than 200 units per day — to help keep their blood sugar levels on target,” Jeffrey A. Jackson, MD, FACE, CDE, medical fellow, U.S. Medical Affairs, Lilly Diabetes, said in a press release when the drug was approved. “For these patients, the U-500 KwikPen is now available as a convenient alternate option to deliver a large dose of insulin in a reasonable volume. It was specifically designed as a dedicated dosing device to eliminate the need for dose conversion, as compared to use of the vial and syringe options, which some people may find to be an improvement.”